Jayagopal Ashwath — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Jayagopal Ashwath has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $58K.
Profile
Ashwath Jayagopal is the Chief Scientific & Development Officer of Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on inherited retinal diseases (IRDs) and other retinal disorders. Based on the SEC filing context (CIK 0002008983, as of 2026-01-27), he holds a leadership role overseeing scientific strategy, research, and development efforts for the company’s ophthalmic gene-therapy programs, including AAV-based approaches addressing diseases such as bestrophinopathies, Leber congenital amaurosis (LCA), and retinitis pigmentosa.
Role
Insider
Notability
45/100
Board memberships
Opus Genetics, Inc.
Awards & honors
Oversight of scientific strategy and development programs for IRD gene therapies at Opus Genetics.
Leadership of translational research and preclinical development for AAV-based ocular therapies.
Guidance of pipeline progression toward clinical-stage initiatives in inherited retinal diseases.
Ashwath Jayagopal is the Chief Scientific & Development Officer of Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on inherited retinal diseases (IRDs) and other retinal disorders. Based on the SEC filing context (CIK 0002008983, as of 2026-01-27), he holds a leadership role overseeing scientific strategy, research, and development efforts for…
How many SEC Form 4 filings has Jayagopal Ashwath submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Has Jayagopal Ashwath been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($58K) across all tracked filings.
Where can I see all of Jayagopal Ashwath's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
